Melinta是Cempra制药公司的继承实体。Cempra制药公司位于北卡罗来纳州教堂山市,于2005年11月18日成立,是一家开发抗细菌...查看全文
用户48783635432019-04-10 11:18
【4月9日医药股盘点】$Histogenics(HSGX)$$PhaseBio制药(PHAS)$ $Melinta Therapeutics(MLNT)$ 细胞疗法公司Histogenics同制药公司Ocugen合并,上涨56%;制药公司PhaseBio Pharmaceuticals上涨17.15%;抗生素开发公司Melinta Therapeutics上涨15.15%等。查看全文网页链接查看全文
$Melinta Therapeutics(MLNT)$ 8-K - Current report Filed: 2019-01-03 AccNo: 0001193125-19-000943 Size: 828 KBItem 1.01: Entry into a Material Definitive AgreementItem 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a R...
$Melinta Therapeutics(MLNT)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2018-12-19 AccNo: 0001193125-18-353220 Size: 121 KB 网页链接
$Melinta Therapeutics(MLNT)$ 8-K - Current report Filed: 2018-12-19 AccNo: 0001193125-18-353219 Size: 121 KBItem 1.01: Entry into a Material Definitive AgreementItem 1.02: Termination of a Material Definitive AgreementItem 2.03: Creation of a Direct Financial Obligation or an...
$Melinta Therapeutics(MLNT)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2018-12-19 AccNo: 0001193125-18-353380 Size: 30 KB 网页链接
$Melinta Therapeutics(MLNT)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2018-12-19 AccNo: 0001193125-18-353388 Size: 30 KB 网页链接
$Melinta Therapeutics(MLNT)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2018-12-20 AccNo: 0001193125-18-354731 Size: 84 KB 网页链接
$Melinta Therapeutics, Inc.(MLNT)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2018-12-20 AccNo: 0001193125-18-354731 Size: 84 KB 网页链接
$Melinta Therapeutics, Inc.(MLNT)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2018-12-19 AccNo: 0001193125-18-353380 Size: 30 KB 网页链接
$Melinta Therapeutics, Inc.(MLNT)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2018-12-19 AccNo: 0001193125-18-353388 Size: 30 KB 网页链接
$Melinta Therapeutics, Inc.(MLNT)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2018-12-19 AccNo: 0001193125-18-353220 Size: 121 KB 网页链接